Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data

Emery, P orcid.org/0000-0002-7429-8482, Furst, DE, Kirchner, P et al. (3 more authors) (2020) Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. Rheumatology and Therapy, 7. pp. 121-131. ISSN 2198-6584

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Keywords: Database; Malignancy; Real-world; Rheumatoid arthritis; Rituximab; Safety
Dates:
  • Accepted: 30 October 2019
  • Published (online): 21 November 2019
  • Published: March 2020
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Institute of Rheumatology & Musculoskeletal Medicine (LIRMM) (Leeds) > Inflammatory Arthritis (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 11 Nov 2019 11:18
Last Modified: 09 Mar 2020 15:25
Status: Published
Publisher: Springer
Identification Number: https://doi.org/10.1007/s40744-019-00183-6

Export

Statistics